title: Consensus statement on prevention and detection of ovarian hyperstimulation syndrome.
abstract: BACKGROUND
  Ovarian hyperstimulation syndrome is an important condition with considerable morbidity and a small risk of mortality, which most commonly results as an iatrogenic condition following follicular stimulation of the ovaries.
  
  
  OBJECTIVE
  To produce evidence-based and consensus statements on the prevention and detection of ovarian hyperstimulation syndrome (OHSS).
  
  
  METHODS
  The CREI Consensus Group met in 2008 and identified issues for inclusion and review. Review of the available evidence was conducted and consensus statements prepared. Areas of dissent of expert opinion and for further research were noted.
  
  
  RESULTS
  The group considered that there is a need for standardisation of the definition and classification of the clinical syndrome of OHSS to allow further conclusive research. Interventions with evidence of effect in reducing OHSS include the use of metformin in women with PCOS, use of GnRH antagonist rather than GnRH agonist and use of GnRH agonist triggers in GnRH antagonist stimulation cycles. The consensus view was that reducing the dose of FSH, freezing all embryos and transferring a single embryo were appropriate interventions to reduce OHSS. Agreement could not be reached on coasting, the lowest number of oocytes to consider freezing all embryos and management after cancellation of oocyte collection.
  
  
  CONCLUSIONS
  OHSS is a serious condition for which there are a number of proven preventative strategies. OHSS is an area requiring ongoing research and development of a universally agreed definition will allow development of optimal prevention strategies and facilitate improved early detection of women at risk.
authors.affiliation: Assisted Conception Australia, Brisbane, Queensland, Australia.
authors.forename: Clare
authors.initials: C
authors.lastname: Boothroyd
authors.affiliation: Genea, Sydney, New South Wales, Australia.|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
authors.forename: Sonal
authors.initials: S
authors.lastname: Karia
authors.affiliation: Assisted Conception Australia, Brisbane, Queensland, Australia.
authors.forename: Natasha
authors.initials: N
authors.lastname: Andreadis
authors.affiliation: Monash IVF, Melbourne, Victoria, Australia.
authors.forename: Luk
authors.initials: L
authors.lastname: Rombauts
authors.affiliation: Fertility Plus and Repromed Auckland, University of Auckland, Auckland, New Zealand.|Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia.
authors.forename: Neil
authors.initials: N
authors.lastname: Johnson
authors.affiliation: Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia.|IVF Australia, Sydney, New South Wales, Australia.
authors.forename: Michael
authors.initials: M
authors.lastname: Chapman
mesh_terms: D032921:Consensus; D015925:Cryopreservation; D004622:Embryo, Mammalian; D019317:Evidence-Based Medicine; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000037:antagonists & inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D016471:Ovarian Hyperstimulation Syndrome / Q000145:classification / Q000150:complications / Q000175:diagnosis* / Q000517:prevention & control*; D011085:Polycystic Ovary Syndrome / Q000150:complications; D012307:Risk Factors; D056826:Single Embryo Transfer
chemical_list: D007004:Hypoglycemic Agents; D007987:Gonadotropin-Releasing Hormone; D005640:Follicle Stimulating Hormone; D008687:Metformin
keywords: diagnosis; ovarian hyperstimulation syndrome; prevention